{
    "nctId": "NCT03499639",
    "officialTitle": "Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study)",
    "inclusionCriteria": "* patients were 18 years old or more,\n* naive to HCV treatment,\n* HCV genotype 4,\n* compensated liver disease.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Patients with combined HCV/HBV co-infection\n* hepatocellular carcinoma (HCC)\n* decompensated liver cirrhosis (Child-Pugh score above 6)\n* non-genotype 4"
}